Straits Times Index
3,306.97 +10.08 (+0.31%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,412.04 +204.91 (+1.13%) FTSE 100
8,172.15 +50.91 (+0.63%) Bitcoin USD
59,583.62 +2,303.00 (+4.02%) CMC Crypto 200
1,286.59 +15.85 (+1.25%)
Biomind Labs Inc. (BMND.NE)
| Previous close | 0.3750 |
| Open | 0.3750 |
| Bid | 0.3000 x N/A |
| Ask | 0.4400 x N/A |
| Day's range | 0.3750 - 0.4500 |
| 52-week range | 0.0250 - 1.2100 |
| Volume | |
| Avg. volume | 3,598 |
| Market cap | 28.036M |
| Beta (5Y monthly) | -0.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireBiomind Labs Announces Unprecedented Positive Results of Phase 2 Clinical Trial of BMND08 for Depression & Anxiety in Alzheimer’s Disease
TORONTO, February 29, 2024--Biomind Labs Inc. ("Biomind" or the "Company") (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, today announced the successful conclusion of the Phase 2 clinical trial of its proprietary 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT")-based BMND08, a sublingual formulation designed for the treatment of de
Business WireBiomind Labs Provides Corporate Update
TORONTO, September 27, 2023--Biomind Labs Inc. ("Biomind Labs" or the "Company") (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, provides a corporate update outlining its research and development, intellectual property and clinical trials initiatives.
Business WireBiomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications
TORONTO, September 14, 2023--Biomind Labs Inc. ("Biomind Labs" or the "Company") (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce the successful completion of the first 5-Metoxi-N,N-dimethyltryptamine ("5-MeO-DMT") organic synthesis scheme. This significant achievement marks a major breakthrough in the devel
